Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Michigan for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Michigan only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Michigan (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Faisal Musa (NPI 1811138787)

Field	Value
Entity Type	Individual
Organization	Faisal Musa
Address	13530 Michigan Ave Ste 280
City	Dearborn
State	MI
ZIP	48126
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 23, 2009

Payer Source	Total Paid
Medicare	$3M
Medicaid	$0

Key Findings

This profile reads like an infusion-based hematology/oncology practice: the top revenue drivers are oncology biologics and immunotherapies rather than routine primary-care E/M billing. The highest-revenue codes are J9271, J9022 and J0897, and these drugs (pembrolizumab, atezolizumab and denosumab) are consistent with an operation focused on in-office infusion of high-cost cancer therapies and bone-health support for oncology patients. 96413, 96365 and administration/add-on codes also appear on the list, reinforcing that drug administration is a core service line.

Revenue is highly concentrated in a small set of products: the precomputed top-3 Medicare codes account for 82.9% of this provider's total Medicare revenue. Individually, J9271 accounts for $1.2M (40.4% of Medicare revenue), J9022 for $753.4K (25.9%), and J0897 for $482.8K (16.6%), which shows most Medicare dollars flow from a narrow set of infused agents. This concentration implies the practice’s financial performance is closely tied to utilization and reimbursement for these specific drugs.

Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $3M while there is no Medicaid billing on file. That absence of Medicaid claims means the provider’s public-payer exposure is concentrated in Medicare beneficiaries, which reduces diversification across state Medicaid programs and could shape contract priorities and patient outreach.

Competitive standing varies by product: for J9022 the provider ranks #3 of 39 nationally and is described as "notably above typical national volume," indicating an unusually large national presence for atezolizumab administration. By contrast J9271 (27.4K claims, $1.2M revenue) ranks #169 of 1841 and is characterized as typical/unremarkable volume, so pembrolizumab activity is sizable but not uniquely dominant versus peers. J0897 ranks #129 of 10057 and is labeled an "extreme outlier," signaling extraordinarily high denosumab billing relative to the national population of providers.

Clinical workload and acuity are elevated: E/M and inpatient initial visit codes show high volumes and high statistical standing, with 99214 at 1.4K claims ($133.2K, 4.6% of Medicare revenue) labeled an "extreme outlier" and 99205 (156 claims, $26.1K) similarly flagged. These patterns suggest the provider manages a steady stream of complex established patients and high-acuity new evaluations in addition to infusion work, consistent with specialist oncology care requiring significant decision making and visit time.

Operational footprint is supported by supportive-care and biosimilar use: pegfilgrastim biosimilar codes Q5108 and Q5122 appear on the list (588 claims, $57.6K and 288 claims, $25.1K respectively), and administration codes such as 96413 (549 claims, $57.1K) are present. This mix indicates the practice provides on-site supportive oncology services (growth factor support, chemotherapy administration) that complement the high-cost oncology agents driving top-line revenue.

Tenure and scale signal an established practice: the NPI was enumerated 2009-03-23 (~17 years ago), and lifetime Medicare revenue of $3M reflects a moderate cumulative Medicare footprint for an individual Hematology & Oncology Physician. Combined with the high claim counts for key drugs (e.g., J9271 27.4K claims, J9022 11.8K claims, J0897 26.8K claims), the provider demonstrates sustained operational activity in infusion oncology over a long tenure.

Concentration-driven opportunities and sensitivities are evident for contracting and risk management. With 82.9% of Medicare revenue tied to three codes and no Medicaid billing on file, the practice could have negotiating leverage for those high-volume agents (especially where national rank is elevated), but it also faces revenue vulnerability if formulary shifts, reimbursement cuts, or utilization changes affect J9271, J9022 or J0897. These dynamics should be considered in payer contracting, utilization review, and network strategy given the asymmetric reliance on specific infused biologics.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

44 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	27,400	$40	$1.2M
J9022	Injection, atezolizumab, 10 mg	11,770	$60	$753.4K
J0897	Injection, denosumab, 1 mg	26,820	$20	$482.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,390	$100	$133.2K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	590	$100	$57.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	550	$100	$57.1K
99223	The provider sees a patient for an initial hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the…	270	$140	$35.8K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	240	$140	$33.7K
J1439	Injection, ferric carboxymaltose, 1 mg	26,250	$1	$26.3K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	160	$170	$26.1K

Showing 1–10 of 44

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 44 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Michigan Distribution

Faisal Musa — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Michigan

Full comparison — all codes billed, vs. state median

44 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9022	1	10	11,770	$60	$754.7K
J9271	3	30	8,800	$40	$473.6K
J0897	2	170	2,460	$20	$69.1K
Q5108	3	10	310	$100	$39.1K
Q5122	3	10	290	$80	$22.6K
J1439	10	30	21,750	$1	$20.3K
96413	7	170	120	$100	$16.1K
Q0138	8	40	29,070	$1	$12.8K
99233	1,369	4,220	70	$90	$12.3K
99232	1,219	6,730	90	$60	$12K

Showing 1–10 of 44

Related Providers

Other providers that share a Tax Identification Number (TIN) with Faisal Musa, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Michigan Healthcare Professionals PC	MI	Internal Medicine Physician	$0	$106.2M
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Somc Medical Care Foundation, Inc.	OH	Family Medicine Physician	$0	$25.3M
Jeffrey Margolis	MI	Hematology & Oncology Physician	$3M	$0
Richard Zekman	MI	Medical Oncology Physician	$1.4M	$0
Ishmael Jaiyesimi	MI	Hematology & Oncology Physician	$1.3M	$0
Joshua Grant	MI	Ophthalmology Physician	$1.3M	$0
Christopher Sweet	MI	Diagnostic Radiology Physician	$1.3M	$0
Susanna Gaikazian	FL	Medical Oncology Physician	$1.2M	$0
Andrew Muskovitz	MI	Hematology & Oncology Physician	$1.2M	$0

Nearby Providers

Other providers in the same ZIP code as Faisal Musa, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Psygenics Inc	MI	Clinical Social Worker	$0	$41.4M
Children's Dental Care PLLC	MI	Pediatric Dentistry	$0	$37.5M
Arab Community Center For Economic And Social Services Access	MI	Community/Behavioral Health Agency	$0	$25.1M
Alzohaili Medical Consultants Md PC	MI	Endocrinology, Diabetes & Metabolism Physician	$0	$13.3M
Patient First Medical Clinic PLLC	MI	Addiction Medicine (Internal Medicine) Physician	$0	$11.6M
Chase Pediatrics	MI	Primary Care Clinic/Center	$0	$11M
Basel Khatib, M.d., P.C.	MI	Pediatrics Physician	$0	$8.3M
Childrens Health Center	MI	Health Service Clinic/Center	$0	$7.3M
Mohamed Ayad, M.d., P.C.	MI	Family Medicine Physician	$0	$6.7M
Ali Sobh	MI	Dentist	$0	$6.3M

Faisal Musa — Billing Profile & Reimbursement Data

Sign up for Faisal Musa — Billing Profile & Reimbursement Data policy alerts

Faisal Musa — Billing Profile & Reimbursement Data

Sign up for Faisal Musa — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References